


gibco



Expand your T cell research

Dynabeads products for T cell activation
and expansion

ThermoFisher
SCIENTIFIC

Physiological T cell activation and expansion

Bridge the gap between mouse and human research

- Easy adaptation of activation duration and intensity
- Activated cells are functional with *in vivo*-like properties
- Restimulate T cells without maintaining APC/feeder cell cultures
- Maximal reproducibility with minimal effort
- Up to 3,000-fold expansion in just 14 days

You no longer have to tediously isolate antigen-presenting cells (APCs) for T cell activation and expansion. And you don't have to worry about loss of T cell function or antigen recognition capability, or even the potential failure to engraft after infusion.

Gibco™ Dynabeads™ T cell expansion products mimic *in vivo* T cell activation by APCs. This gentle and efficient technology allows *ex vivo* physiological activation and expansion of both mouse and human T cells (Figure 1).




Figure 1. Overview of the simple and efficient Dynabeads T cell activation and expansion products. If you are using Gibco™ Dynabeads™ Human T-Expander (Cat. No. 11141D) or CTS™ Dynabeads™ CD3/CD28* (Cat. No. 40203D), these can be used for both T cell isolation and activation/expansion.

How it works

The T cell activation workflow couldn't be easier. Dynabeads products provide key signals to CD3/TCR and CD28, simultaneously (Figures 2 and 3). Following activation and expansion, the bead-free T cells retain functional properties [2]. The cells can be restimulated several times; simply change the medium and add more beads (Figure 4). The whole process is antigen-independent, gentle, and efficient.




Figure 2. Consistent and reliable T cell activation. Dynabeads T cell activation products offer a simple solution for mimicking the *in vivo* interaction of T cells with antigen-presenting cells (APCs) by utilizing the two activation signals present on APCs (CD3 and CD28) conjugated to magnetic beads.




Figure 3. Dynabeads products for specific stimulation and expansion of T cells. The image shows activated T cells and Dynabeads CD3/CD28.




Figure 4. Expanded human regulatory T cells (Treg) retain their phenotype and functionality. Human Treg cells were isolated using the Gibco™ Dynabeads™ Regulatory CD4⁺/CD25⁺ T Cell Kit, followed by activation using Dynabeads™ Human Treg Expander. **(A)** The Treg cells are expanded 100-fold (dark blue). Higher expansion can be obtained by restimulating the cells at day 8, starting with >97% pure Treg cells (light blue). **(B)** Expanded human Treg cells were co-cultured with allogenic PBMCs for 6 days at various suppressor:responder ratios. Proliferation was measured using a standard thymidine incorporation assay. At a 1:1 ratio, 80% suppression was achieved.

Quick, easy, and efficient

When you're using Dynabeads technology, there's no need for autologous APCs or antigen, and you don't have to worry about APC/feeder cell contamination or culture maintenance. Benefits include:

- Ease of use—just add beads
- Consistent, simultaneous signaling via CD3/CD28
- No negative signaling through CTLA4
- Expansion of CD4⁺, CD8⁺, and Treg cells
- Products ranging from mouse and human research to clinical research

Quality and consistency

Dynabeads products bring reproducibility and robustness to T cell activation and expansion. Stable beads with precise amounts of anti-CD3 and anti-CD28 antibodies help ensure that the stimulated T cells retain their functional phenotype after proliferation. Yet there are no contaminating by-products such as antibodies, beads, or feeder cells.

The expanded T cells are induced to express a wide array of immunomodulatory molecules (including CD137 and CD40L) [2] and cytokines such as IL-2, IFN- γ , TNF- α , and GM-CSF [3]. Surface CD28 and CD62L expression is maintained, and key homing receptors (e.g., L-selectin) and survival molecules (Bcl-XL) are induced [1,2]. Additionally:

- A broad T cell repertoire is maintained, securing antigen recognition capabilities [3]
- Expansion can reverse anergy and restore immunological responses [4]
- Expanded CD4⁺ and CD8⁺ cells retain their cytolytic and helper functions
- Expanded Treg cells retain their suppressive activity [5]
- Bead-activated T cells are easy to transduce [6]



Efficient expansion of Ag-specific T cells

The main application for these products is T cell re-stimulation and expansion of antigen-specific (Ag-specific) T cells from cell lines or cell clones, or freshly isolated/enriched Ag-specific T cells (Figure 5).

Key benefits:

- **Physiological activation:** stimulation of CD3, CD28, and CD137 cells with agonistic monoclonal antibodies
- **Efficiency:** increased expansion and survival of Ag-specific T cells
- **Reliability:** T cells expanded with Dynabeads products maintain antigen specificity when tested in bioassays
- **Ease of use:** no need to find or prepare donor-matched APCs or antigen




Figure 5. To enable expansion of human antigen-specific T cells, Dynabeads products are conjugated with anti-CD3, anti-CD28, and anti-CD137 antibodies. CD137 (4-1BB) is a member of the tumor necrosis factor family, and agonistic anti-CD137 antibodies act as activating co-stimulatory molecules, especially important for effector/memory T cells, and promote the survival and proliferation of T lymphocytes. This technology allows you to activate and/or expand naïve and memory T cells, T cell clones, regulatory T cells, NKT cells, and CTLs from mouse and human samples.

From mouse models to clinical trials

Expanded mouse T cells can be used for *in vitro* manipulations or for adoptive transfer. This is relevant for mouse models for human diseases, including the study of infectious diseases, autoimmunity, transplantation, and cancer. Immunotherapy based on antigen-specific T cells is

being applied to a growing range of disease treatments [7].

The portfolio of activation and expansion Dynabeads products also includes a clinical research-grade product, allowing you to move from mouse studies to clinical research using the same technology platform. For scale-up in translational research, the Gibco™ CTS™ DynaMag™ Magnet** has been developed for optimal performance with CTS Dynabeads CD3/CD28 beads.

Dynabeads products are the gold standard for T cell research ranging from fundamental studies to T cell-based therapy and have numerous citations in scientific literature (e.g., [8-20]).

Ordering information*

Product	Quantity	Cat. No.
Dynabeads Mouse T-Activator CD3/CD28	0.4 mL	11456D
	2 mL	11452D
	5 x 2 mL	11453D
Dynabeads Human T-Activator CD3/CD28	0.4 mL	11161D
	2 mL	11131D
	5 x 2 mL	11132D
Dynabeads Human T-Activator CD3/CD28/CD137	0.4 mL	11162D
	2 mL	11163D
Dynabeads Human T-Expander CD3/CD28	10 mL	11141D
Dynabeads Human Treg Expander	2 mL	11129D
CTS Dynabeads CD3/CD28*	10 mL	40203D
CTS Dynabeads Treg Xpander*	10 mL	46000D
Related products		
CTS Immune Cell Serum Replacement*	50 mL	A2596101
	500 mL	A2596102
DynaMag-15 Magnet (holds 4 standard 15 mL tubes, alternatively 4 standard FACS tubes)	1 unit	12301D
DynaMag-50 Magnet (holds two 5–50 mL tubes)	1 unit	12302D
DynaMag-5 Magnet (holds 8 standard FACS tubes)	1 unit	12303D
CTS DynaMag Magnet**	1 unit	12102
CTS OpTmizer T-Cell Expansion SFM (for human T cells, bottle format) [†]	1 L	A1048501
CTS OpTmizer T-Cell Expansion SFM (for human T cells, bag format) [†]	1 L	A1048503
HulaMixer Sample Mixer (compatible with 2–50 mL tubes)	1 unit	15920D

References

1. Berger C et al. (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. *Blood* 101:476–484.
2. Bonyhadi M et al. (2005) *In vitro* engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. *J Immunol* 174(4):2366–2375.
3. Hami L et al. (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. *BioProcessing J* 2(6):23–34.
4. Levine BL et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreases CCR5 expression in HIV infection. *Nat Med* 8(1):47–53.
5. Godfrey WR et al. (2004) *In vitro* expanded human CD4⁺CD25⁺ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. *Blood* 104(2):453–461.
6. Coito S et al. (2004) Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation-and transduction/selection-dependent TCR-B variable chain repertoire skewing of gene-modified cells. *Stem Cells Dev* 13(1):71–81.
7. Rapoport AP et al. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. *Nat Med* 11(11):1230–1237.
8. Hollyman D et al. (2009) Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. *J Immunother* 32(2):169–180.
9. Bere A et al. (2010) Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush-derived T cells from the female genital tract of HIV-infected women. *J Immunol Methods* 354:68–79.
10. Teschner D et al. (2011) *In vitro* stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28 magnetic beads. *Scand J Immunol* 74(2):155–164.
11. Guo X et al. (2012) *In vitro*-expanded CD4(+)CD25(high)Foxp3(+) regulatory T cells controls corneal allograft rejection. *Hum Immunol* 73(11):1061–1067.
12. Shi T et al. (2012) Impact of polyclonal anti-CD3/CD28-coated magnetic bead expansion methods on T cell proliferation, differentiation and function. *Int Immunopharmacol* 15(1):129–137.
13. Cieri N et al. (2013) IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. *Blood* 121(4):573–584.
14. Onlamoon N et al. (2013) Influence of cell isolation method on the optimization of CD4+ T cell expansion using anti-CD3/CD28 coated beads. *Asian Pac J Allergy Immunol* 3(2):99–105.
15. Almásbak H et al. (2015) Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. *Gene Ther* 22(5):391–403.
16. Smith C et al. (2015) Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement. *Clin Transl Immunology* 4(1):e31.
17. Matheu M et al. (2015) Imaging regulatory T cell dynamics and CTLA4-mediated suppression of T cell priming. *Nat Commun* 6:6219.
18. Feng Y et al. (2015) A mechanism for expansion of regulatory T cell repertoire and its role in self tolerance. *Nature* 528(7580):132–136.
19. Huynh A et al. (2015) Control of PI(3) kinase in Treg cells maintains homeostasis and lineage stability. *Nat Immunol* 16:188–196.
20. Nguyen H et al. (2016) Naïve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF- β immunosuppression in the tumor microenvironment. *Sci Rep* 6:28208.



* For Research Use or Non-Commercial Manufacturing of Cell-Based Products for Clinical Research. Caution: Not intended for direct administration into humans or animals.

** For Research Use Only or Manufacturing of Cell, Gene, or Tissue-Based Products. Caution: Not intended for direct administration into humans or animals.

† For Human Ex Vivo Tissue and Cell Culture Processing Applications. Caution: When used as a medical device, Federal Law restricts this device to sale by or on the order of a physician.

Find out more at thermofisher.com/tcellactivation

ThermoFisher
S C I E N T I F I C

Unless otherwise indicated all products are For Research Use Only. Not for use in diagnostic procedures. © 2019 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. COL010868 1219